probiotic formulas probiotics ps...rds cfu ntarum (lp-115) /mil liards cfu ì ì í /mil liards cfu...
TRANSCRIPT
Probiotic FormulasModify and Promote Healthy Gut Flora Proven Stability, Safety & Efficacy
Supreme-PB30+ DFFor IBS, candidiasis, celiac disease, food sensitivity/ leaky gut syndrome, dyspepsia, peptic ulcer disease, as well as prevention of acute infectious and antibiotic-associated diarrhea.
S. boulardiiTake with antibiotics to prevent antibiotic-associated diarrhea, acute traveller’s diarrhea, C. difficile infections, and decrease side effects during H. pylori eradication treatment.
Dairy Free / Sans produits laitiers
Helps to manage acute infectious diarrhoea, reduce the risk of
antibiotic-associated diarrhoea, and support gastrointestinal health.
Contrôle de la diarrhée infectieuse aiguë; réduction du risque de
diarrhée associée aux antibiotiques; and contribue à soutenir la
santé gastrointestinale.
Ingr
edie
nts/
Ingr
édie
nts (
per s
coop
/ par
cuill
ère)
:
Bifid
obac
teriu
m b
reve
(BB-
03)..
......
......
......
....1
bill
ion/
mill
iard
s cfu
Bifid
obac
teriu
m in
fanti
s (BI
-26)
......
......
......
....1
bill
ion/
mill
iard
s cfu
Bifid
obac
teriu
m b
ifidu
m (B
B-06
).....
......
......
0.5
billi
on/m
illia
rds c
fu
Bifid
obac
teriu
m la
ctis (
BL-0
4)...
......
......
......
.1.5
bill
ion/
mill
iard
s cfu
Lact
obac
illus
acid
ophi
lus (
LA-1
4)...
......
......
..1.5
bill
ion/
mill
iard
s cfu
Lact
obac
illus
case
i (LC
-11)
......
......
......
......
.....1
bill
ion/
mill
iard
s cfu
Lact
obac
illus
pla
ntar
um (L
P-11
5)...
......
......
.1.5
bill
ion/
mill
iard
s cfu
Lact
obac
illus
rham
nosu
s (GG
).....
......
......
......
2 b
illio
n/m
illia
rds c
fu
Lact
obac
illus
rham
nosu
s (HN
001)
......
......
......
2 bi
llion
/mill
iard
s cfu
Lact
obac
illus
rham
nosu
s (LR
-32)
......
......
.....1
.5 b
illio
n/m
illia
rds c
fu
Lact
obac
illus
reut
eri (
1E1)
......
......
......
......
...0.
5 b
illio
n/m
illia
rds c
fu
Lact
obac
illus
saliv
ariu
s (LS
-33)
......
......
......
.....1
bill
ion/
mill
iard
s cfu
Stre
ptoc
occu
s the
rmop
hilu
s (ST
-21)
......
......
...1
billi
on/m
illia
rds c
fu
*May
con
tain
up
to 2
5 bi
llion
via
ble
cells
per
cap
sule
at t
he �
me
of m
anuf
actu
re./
Peut
con
teni
r ju
squ’
à 25
mill
iard
s de
cel
lule
s
viab
les p
ar ca
psul
e au
mom
ent d
e la
fabr
ica�o
n.
Non-
med
icina
l Ing
redi
ents
/ Ing
rédi
ents
Non
-méd
icina
ux:
inul
in/ i
nulin
e, m
alto
dext
rin/ m
alto
dext
rine,
pul
lula
n/
hypr
omel
lose
(cap
sule
)
Sugg
este
d Us
e/ U
�lisa
�on
Sugg
érée
:
For A
cute
Infe
c�ou
s Dia
rrhe
a: T
ake
1 sc
oop,
3 �
mes
a d
ay.
For R
educ
ing
the
Risk
of A
n�bi
o�c-
Asso
ciate
d Di
arrh
ea: T
ake
2
scoo
ps, 3
�m
es a
day
. Or a
s dire
cted
by
a he
alth
care
pra
c��o
ner./
Pour
la d
iarr
hée
infe
c�eu
se a
iguë
: Pre
ndre
1 c
uillè
re, 3
fois
par
jour
. Réd
uc�o
n du
risq
ue d
e di
arrh
ée a
ssoc
iée
aux a
n�bi
o�qu
es:
Pren
dre
2 cu
illèr
e, 3
foi
s pa
r jo
ur.
Ou s
uivr
e le
s co
nsei
ls
d’u�
lisa�
on d
e vo
tre
pra�
cien
de sa
nté.
Cau�
on/ M
ise e
n Ga
rde:
If yo
u ha
ve fe
ver,
vom
i�ng
, blo
ody d
iarr
hoea
or s
ever
e ab
dom
inal
pain
, con
sult
a he
alth
car
e pr
ac��
oner
prio
r to
use.
If sy
mpt
oms
of d
iges
�ve
upse
t (e.
g. d
iarr
hea)
occ
ur, w
orse
n, o
r per
sist b
eyon
d
3 da
ys, d
iscon
�nue
use
and
cons
ult a
hea
lth ca
re p
rac�
�one
r. Do
not
use
this
prod
uct
if yo
u ha
ve a
n im
mun
e-co
mpr
omise
d
cond
i�on
(e.
g. A
IDS,
lym
phom
a, p
a�en
ts u
nder
goin
g lo
ng-te
rm
cor�
cost
eroi
d tr
eatm
ent).
/ Si
vo
us
souff
rez
de
fièvr
e,
de
vom
issem
ents
, de
diar
rhée
sang
lant
e ou
de
doul
eurs
abdo
min
ales
inte
nses
, con
sulte
r un
pra�
cien
de so
ins d
e sa
nté
avan
t d'e
n fa
ire
l'usa
ge. S
i des
sym
ptôm
es d
e tr
oubl
es d
iges
�fs (
p. e
x. d
iarr
hée)
se
man
ifest
ent,
s'agg
rave
nt e
t/ou
per
siste
nt a
u-de
là
de 3
jou
rs,
cess
er l
'u�l
isa�o
n et
con
sulte
r un
pra�
cien
de s
oins
de
sant
é. S
i vou
s so
uffre
z d'
un
défic
it im
mun
itaire
(p. e
x. si
da, l
ymph
ome,
pa�
ents
subi
ssan
t un
tr
aite
men
t pr
olon
gé
aux
cor�
cost
éroï
des)
, ne
pas u
�lise
r ce
prod
uit.
Stor
e un
der r
efrig
era�
on (b
elow
8˚C
). Pl
ease
fini
sh
cons
umin
g th
e pr
oduc
t w
ithin
30
da
ys
a�er
open
ing.
Do
not u
se if
cap
seal
is b
roke
n./ M
aint
enir
sous
réfri
géra
�on
(au-
dess
ous d
e 8˚
C). S
’il vo
us p
laît
term
iner
le p
rodu
it es
t con
som
mé
dans
les 3
0 jo
urs
aprè
s ou
vert
ure.
Ne
pas
u�lis
er s
i le
sce
au d
u
capu
chon
est
bris
é.
Man
ufac
ture
d by
/ Fab
riqué
par
:
Natu
ro A
id P
harm
aceu
�cal
Inc.
Map
le R
idge
, B.C
., V2
X 8G
1, C
anad
a
ww
w.vi
taai
d.co
m
56 servings
Vegan Fo
rmula
s
Form
ules
Vegan
Baby &
M m
PB15+ D�F
Baby & Mom-PB15+ DFFormulation specifically designed to support immune system for infants, toddlers and pregnant/ breastfeeding moms. Contains effective strains to promote healthy development and prevent atopic disease for babies, and reduce the risk of gestational diabetes.
Dairy Free / Sans produits laitiers
Helps to manage acute infectious diarrhoea, reduce the risk of antibiotic-associated diarrhoea, and support gastrointestinal health.
Contrôle de la diarrhée infectieuse aiguë; réduction du risque de diarrhée associée aux antibiotiques; and contribue à soutenir la santé gastrointestinale.
Ingr
edie
nts/
Ingr
édie
nts (
per/
par
cap
sule
):Bi
fidob
acte
rium
bifi
dum
(BB-
06)..
......
......
......
......
0.4
billi
on/m
illia
rds c
fuBi
fidob
acte
rium
bre
ve (B
B-03
).....
......
......
......
......
.0.6
bill
ion/
mill
iard
s cfu
Bifid
obac
teriu
m la
ctis (
BL-0
4)...
......
......
......
......
....1
.6 b
illio
n/m
illia
rds c
fuLa
ctob
acill
us a
cido
philu
s (LA
-14)
......
......
......
......
..2.1
bill
ion/
mill
iard
s cfu
Lact
obac
illus
cas
ei (L
C-11
).....
......
......
......
......
......
0.6
bill
ion/
mill
iard
s cfu
Lact
obac
illus
pla
ntar
um (L
P-11
5)...
......
......
......
....1
.5 b
illio
n/m
illia
rds c
fuLa
ctob
acill
us rh
amno
sus (
GG)..
......
......
......
......
....1
.2 b
illio
n/m
illia
rds c
fuLa
ctob
acill
us rh
amno
sus (
LR-3
2)...
......
......
......
......
..1 b
illio
n/m
illia
rds c
fuLa
ctob
acill
us sa
livar
ius (
LS-3
3)...
......
......
......
......
..0.6
bill
ion/
mill
iard
s cfu
Stre
ptoc
occu
s the
rmop
hilu
s (ST
-21)
......
......
......
...0.
5 bi
llion
/mill
iard
s cfu
*May
con
tain
up
to 1
8 bi
llion
via
ble
cells
per
cap
sule
at
the
�me
of
man
ufac
ture
./ P
eut c
onte
nir j
usqu
’à 1
8 m
illia
rds d
e ce
llule
s via
bles
par
ca
psul
e au
mom
ent d
e la
fabr
ica�
on.
Non
-med
icin
al In
gred
ient
s/ In
gréd
ient
s Non
-méd
icin
aux:
Inul
in/in
ulin
e,
mal
tode
xtrin
/ mal
tode
xtrin
e, L-
leuc
ine,
pul
lula
n/ h
ypro
mel
lose
(cap
sule
)Su
gges
ted
Use
/ U
�lis
a�on
Sug
géré
e:
For G
ener
al U
se: T
ake
1 ca
psul
e 1
- 3 �
mes
per
day
, or a
s dire
cted
by
a he
alth
care
pra
c��o
ner.
For A
cute
Infe
c�ou
s Dia
rrhe
a: T
ake
2 ca
psul
es,
3 �m
es a
day
. For
Red
ucin
g th
e Ri
sk o
f An�
bio�
c-As
soci
ated
Dia
rrhe
a:
Take
4 c
apsu
les,
3 �
mes
a d
ay./
À
usag
e gé
néra
l: Pr
endr
e 1
caps
ule
1 à
3 fo
is pa
r jo
ur, o
u su
ivre
les
cons
eils
d’u�
lisa�
on d
e vo
tre
pra�
cien
de
sant
é. P
our
la d
iarr
hée
infe
c�eu
se a
iguë
: Pr
endr
e 2
caps
ules
, 3
fois
par
jour
. Ré
duc�
on d
u ris
que
de d
iarr
hée
asso
ciée
aux
an�
bio�
ques
: Pre
ndre
4 c
apsu
les,
3
fois
par j
our.
Cau�
on/
Mis
e en
Gar
de:
If yo
u ha
ve fe
ver,
vom
i�ng
, blo
ody
diar
rhoe
a or
seve
re a
bdom
inal
pai
n,
cons
ult a
hea
lth c
are
prac
��on
er p
rior t
o us
e. If
sym
ptom
s of d
iges
�ve
upse
t (e
.g.
diar
rhea
) oc
cur,
wor
sen,
or
pe
rsist
be
yond
3
days
, di
scon
�nue
use
and
con
sult
a he
alth
car
e pr
ac��
oner
. Do
not u
se th
is pr
oduc
t if
you
have
an
imm
une-
com
prom
ised
cond
i�on
(e.
g. A
IDS,
ly
mph
oma,
pa�
ents
und
ergo
ing
long
-ter
m c
or�c
oste
roid
trea
tmen
t)./
Si
vou
s so
uffre
z de
fièv
re, d
e vo
miss
emen
ts, d
e di
arrh
ée s
angl
ante
ou
de d
oule
urs
abdo
min
ales
inte
nses
, con
sulte
r un
pra
�cie
n de
soi
ns d
e sa
nté
avan
t d'e
n fa
ire l'
usag
e. S
i des
sym
ptôm
es d
e tr
oubl
es d
iges
�fs (
p.
ex. d
iarr
hée)
se
man
ifest
ent,
s'agg
rave
nt, o
u pe
rsist
ent
au-d
elà
de 3
jo
urs,
ces
ser l
'u�l
isa�o
n et
con
sulte
r un
pra�
cien
de
soin
s de
san
té. S
i vo
us s
ouffr
ez d
'un
défic
it im
mun
itaire
(p. e
x. s
ida,
lym
phom
e, p
a�en
ts
subi
ssan
t un
trai
tem
ent p
rolo
ngé
aux
cor�
cost
éroï
des)
, ne
pas
u�lis
er
ce p
rodu
it.
Stor
e un
der
refr
iger
a�on
(be
low
8˚C
). Pl
ease
fini
sh c
onsu
min
g th
e pr
oduc
t with
in 6
0 da
ys a
�er o
peni
ng. D
o no
t use
if c
ap s
eal i
s br
oken
./
Mai
nten
ir so
us ré
frig
éra�
on (a
u-de
ssou
s de
8˚C)
. S’il
vou
s pla
ît te
rmin
er
le p
rodu
it es
t co
nsom
mé
dans
les
60 j
ours
apr
ès o
uver
ture
. N
e pa
s u�
liser
si le
scea
u du
cap
ucho
n es
t bris
é.
Man
ufac
ture
d by
/ Fab
riqué
par
: Nat
uro
Aid
Phar
mac
eu�c
al In
c.M
aple
Rid
ge, B
.C.,
V2X
8G1,
Can
ada
| w
ww
.vita
aid.
com
56 Vegetarian Capsules
Optimum
PB10+ DF with FOS | avec FOS
Vegan
Form
ulas
Form
ules
Veg
an
Optimum-PB10+ DFFor prevention of dysbiosis caused by antibiotics and general immune and digestive support. Dairy Free / Sans produits laitiers
Helps to manage acute infectious diarrhoea, reduce
the risk of antibiotic-associated diarrhoea, and
support gastrointestinal health.
Contrôle de la diarrhée infectieuse aiguë; réduction
du risque de diarrhée associée aux antibiotiques;
and contribue à soutenir la santé gastrointestinale.
Ingr
edie
nts/
Ingr
édie
nts (
per/
par
caps
ule)
:
Bifid
obac
teriu
m b
ifidu
m (B
B-06
).....
......
......
......
...0.
4 bi
llion
/mill
iard
s cfu
Bifid
obac
teriu
m b
reve
(BB-
03)..
......
......
......
......
....0
.6 b
illio
n/m
illia
rds c
fu
Bifid
obac
teriu
m la
ctis (
BL-0
4)...
......
......
......
......
....1
.6 b
illio
n/m
illia
rds c
fu
Lact
obac
illus
acid
ophi
lus (
LA-1
4)...
......
......
......
.....2
.1 b
illio
n/m
illia
rds c
fu
Lact
obac
illus
case
i (LC
-11)
......
......
......
......
......
.....0
.6 b
illio
n/m
illia
rds c
fu
Lact
obac
illus
pla
ntar
um (L
P-11
5)...
......
......
......
....1
.5 b
illio
n/m
illia
rds c
fu
Lact
obac
illus
rham
nosu
s (GG
).....
......
......
......
......
.1.2
bill
ion/
mill
iard
s cfu
Lact
obac
illus
rham
nosu
s (LR
-32)
......
......
......
......
.....1
bill
ion/
mill
iard
s cfu
Lact
obac
illus
saliv
ariu
s (LS
-33)
......
......
......
......
.....0
.6 b
illio
n/m
illia
rds c
fu
Stre
ptoc
occu
s the
rmop
hilu
s (ST
-21)
......
......
......
...0.
5 bi
llion
/mill
iard
s cfu
*May
con
tain
up
to 1
8 bi
llion
via
ble
cells
per
cap
sule
at
the
�me
of
man
ufac
ture
./ Pe
ut co
nten
ir ju
squ’
à 18
mill
iard
s de
cellu
les v
iabl
es p
ar
caps
ule
au m
omen
t de
la fa
brica
�on.
Non-
med
icina
l Ing
redi
ents
/ Ing
rédi
ents
Non
-méd
icina
ux: I
nulin
/inul
ine,
mal
tode
xtrin
/ mal
tode
xtrin
e, L-
leuc
ine,
pul
lula
n/ h
ypro
mel
lose
(cap
sule
)
Sugg
este
d Us
e/ U
�lisa
�on
Sugg
érée
:
For G
ener
al U
se: T
ake
1 ca
psul
e 1
- 3 �
mes
per
day
, or a
s dire
cted
by
a
heal
th ca
re p
rac�
�one
r. Fo
r Acu
te In
fec�
ous D
iarr
hea:
Tak
e 2
caps
ules
,
3 �m
es a
day
. For
Red
ucin
g th
e Ri
sk o
f An�
bio�
c-As
socia
ted
Diar
rhea
:
Take
4 ca
psul
es, 3
�m
es a
day
./
À us
age
géné
ral:
Pren
dre
1 ca
psul
e 1
à 3
fois
par
jour
, ou
suiv
re le
s
cons
eils
d’u�
lisa�
on d
e vo
tre
pra�
cien
de s
anté
. Po
ur l
a di
arrh
ée
infe
c�eu
se a
iguë
: Pre
ndre
2 c
apsu
les,
3 fo
is pa
r jo
ur. R
éduc
�on
du
risqu
e de
dia
rrhé
e as
socié
e au
x an
�bio
�que
s: P
rend
re 4
cap
sule
s, 3
fois
par j
our.
Cau�
on/ M
ise e
n Ga
rde:
If yo
u ha
ve fe
ver,
vom
i�ng
, blo
ody d
iarr
hoea
or s
ever
e ab
dom
inal
pai
n,
cons
ult a
hea
lth ca
re p
rac�
�one
r prio
r to
use.
If sy
mpt
oms o
f dig
es�v
e
upse
t (e
.g.
diar
rhea
) oc
cur,
wor
sen,
or
pe
rsist
be
yond
3
days
,
disc
on�n
ue u
se a
nd c
onsu
lt a
heal
th c
are
prac
��on
er. D
o no
t use
this
prod
uct
if yo
u ha
ve a
n im
mun
e-co
mpr
omise
d co
ndi�
on (
e.g.
AID
S,
lym
phom
a, p
a�en
ts u
nder
goin
g lo
ng-te
rm co
r�co
ster
oid
trea
tmen
t)./
Si v
ous
souff
rez
de fi
èvre
, de
vom
issem
ents
, de
diar
rhée
san
glan
te o
u
de d
oule
urs
abdo
min
ales
inte
nses
, con
sulte
r un
pra
�cie
n de
soi
ns d
e
sant
é av
ant d
'en
faire
l'usa
ge. S
i des
sym
ptôm
es d
e tr
oubl
es d
iges
�fs (
p.
ex. d
iarr
hée)
se
man
ifest
ent,
s'agg
rave
nt, o
u pe
rsist
ent
au-d
elà
de 3
jour
s, ce
sser
l'u�
lisa�
on e
t con
sulte
r un
pra�
cien
de so
ins
de s
anté
. Si
vous
souff
rez d
'un
défic
it im
mun
itaire
(p. e
x. si
da, l
ymph
ome,
pa�
ents
subi
ssan
t un
trai
tem
ent p
rolo
ngé
aux
cor�
cost
éroï
des)
, ne
pas
u�lis
er
ce p
rodu
it.
Stor
e un
der
refri
gera
�on
(bel
ow 8
˚C).
Plea
se fi
nish
con
sum
ing
the
prod
uct w
ithin
60
days
a�e
r ope
ning
. Do
not u
se if
cap
seal
is b
roke
n./
Mai
nten
ir so
us ré
frigé
ra�o
n (a
u-de
ssou
s de
8˚C)
. S’il
vous
pla
ît te
rmin
er
le p
rodu
it es
t co
nsom
mé
dans
les
60 jo
urs
aprè
s ou
vert
ure.
Ne
pas
u�lis
er si
le sc
eau
du ca
puch
on e
st b
risé.
Man
ufac
ture
d by
/ Fab
riqué
par
: Nat
uro
Aid
Phar
mac
eu�c
al In
c.
Map
le R
idge
, B.C
., V2
X 8G
1, C
anad
a |
ww
w.vi
taai
d.co
m
56 Vegetarian Capsules
Optimum
PB10+ DF with FOS | avec FOS
Vegan Fo
rmula
s
Form
ules
Vegan
Dairy Free / Sans produits laitiers
Helps to manage acute infectious diarrhoea, reduce the risk of
antibiotic-associated diarrhoea, and support gastrointestinal health.
Contrôle de la diarrhée infectieuse aiguë; réduction du risque de
diarrhée associée aux antibiotiques; and contribue à soutenir la
santé gastrointestinale.
Ingr
edie
nts/
Ingr
édie
nts (
per s
coop
/ par
cuill
ère)
:
Bifid
obac
teriu
m b
reve
(BB-
03)..
......
......
......
....5
bill
ion/
mill
iard
s cfu
Bifid
obac
teriu
m in
fanti
s (BI
-26)
......
......
......
....1
bill
ion/
mill
iard
s cfu
Bifid
obac
teriu
m b
ifidu
m (B
B-06
).....
......
......
...2
billi
on/m
illia
rds c
fu
Bifid
obac
teriu
m la
ctis (
BL-0
4)...
......
......
......
..12
billi
on/m
illia
rds c
fu
Lact
obac
illus
acid
ophi
lus (
LA-1
4)...
......
......
...15
bill
ion/
mill
iard
s cfu
Lact
obac
illus
case
i (LC
-11)
......
......
......
......
...10
bill
ion/
mill
iard
s cfu
Lact
obac
illus
pla
ntar
um (L
P-11
5)...
......
......
..15
billi
on/m
illia
rds c
fu
Lact
obac
illus
rham
nosu
s (GG
).....
......
......
......
6 b
illio
n/m
illia
rds c
fu
Lact
obac
illus
rham
nosu
s (HN
001)
......
......
......
3 bi
llion
/mill
iard
s cfu
Lact
obac
illus
rham
nosu
s (LR
-32)
......
......
......
15 b
illio
n/m
illia
rds c
fu
Lact
obac
illus
reut
eri (
1E1)
......
......
......
......
......
1 b
illio
n/m
illia
rds c
fu
Lact
obac
illus
saliv
ariu
s (LS
-33)
......
......
......
.....8
bill
ion/
mill
iard
s cfu
Stre
ptoc
occu
s the
rmop
hilu
s (ST
-21)
......
......
...8
billi
on/m
illia
rds c
fu
*May
cont
ain
up to
200
bill
ion
viab
le ce
lls p
er ca
psul
e at
the
�me
of m
anuf
actu
re./
Peut
con
teni
r jus
qu’à
200
mill
iard
s de
cel
lule
s
viab
les p
ar ca
psul
e au
mom
ent d
e la
fabr
ica�o
n.
Non-
med
icina
l Ing
redi
ents
/ Ing
rédi
ents
Non
-méd
icina
ux:
mal
tode
xtrin
/ mal
tode
xtrin
e, p
ullu
lan/
hyp
rom
ello
se (c
apsu
le)
Sugg
este
d Us
e/ U
�lisa
�on
Sugg
érée
:
For A
cute
Infe
c�ou
s Dia
rrhe
a: T
ake
1 sc
oop,
1-3
�m
es a
day
.
For R
educ
ing
the
Risk
of A
n�bi
o�c-
Asso
ciate
d Di
arrh
ea: T
ake
1
scoo
ps,
2-3
�mes
a d
ay.
Or a
s di
rect
ed b
y a
heal
th c
are
prac
��on
er./
Pour
la d
iarr
hée
infe
c�eu
se a
iguë
: Pre
ndre
1 c
uillè
re, 1
à 3
fois
par
jour
.Réd
uc�o
n du
ris
que
de
diar
rhée
as
socié
e au
x
an�b
io�q
ues:
Pre
ndre
1 cu
illèr
e, 2
à 3
fois
par j
our.
Ou su
ivre
les
cons
eils
d’u�
lisa�
on d
e vo
tre
pra�
cien
de sa
nté.
Cau�
on/ M
ise e
n Ga
rde:
If yo
u ha
ve fe
ver,
vom
i�ng
, blo
ody d
iarr
hoea
or s
ever
e ab
dom
inal
pain
, con
sult
a he
alth
car
e pr
ac��
oner
prio
r to
use.
If sy
mpt
oms
of d
iges
�ve
upse
t (e.
g. d
iarr
hea)
occ
ur, w
orse
n, o
r per
sist b
eyon
d
3 da
ys, d
iscon
�nue
use
and
cons
ult a
hea
lth ca
re p
rac�
�one
r. Do
not
use
this
prod
uct
if yo
u ha
ve a
n im
mun
e-co
mpr
omise
d
cond
i�on
(e.
g. A
IDS,
lym
phom
a, p
a�en
ts u
nder
goin
g lo
ng-te
rm
cor�
cost
eroi
d tr
eatm
ent).
/ Si
vo
us
souff
rez
de
fièvr
e,
de
vom
issem
ents
, de
diar
rhée
sang
lant
e ou
de
doul
eurs
abdo
min
ales
inte
nses
, con
sulte
r un
pra�
cien
de so
ins d
e sa
nté
avan
t d'e
n fa
ire
l'usa
ge. S
i des
sym
ptôm
es d
e tr
oubl
es d
iges
�fs (
p. e
x. d
iarr
hée)
se
man
ifest
ent,
s'agg
rave
nt e
t/ou
per
siste
nt a
u-de
là
de 3
jou
rs,
cess
er l
'u�l
isa�o
n et
con
sulte
r un
pra�
cien
de s
oins
de
sant
é. S
i vou
s so
uffre
z d'
un
défic
it im
mun
itaire
(p. e
x. si
da, l
ymph
ome,
pa�
ents
subi
ssan
t un
tr
aite
men
t pr
olon
gé
aux
cor�
cost
éroï
des)
, ne
pas u
�lise
r ce
prod
uit.
Stor
e un
der r
efrig
era�
on (b
elow
8˚C
). Pl
ease
fini
sh
cons
umin
g th
e pr
oduc
t w
ithin
30
da
ys
a�er
open
ing.
Do
not u
se if
cap
seal
is b
roke
n./ M
aint
enir
sous
réfri
géra
�on
(au-
dess
ous d
e 8˚
C). S
’il vo
us p
laît
term
iner
le p
rodu
it es
t con
som
mé
dans
les 3
0 jo
urs
aprè
s ou
vert
ure.
Ne
pas
u�lis
er s
i le
sce
au d
u
capu
chon
est
bris
é.
Man
ufac
ture
d by
/ Fab
riqué
par
:
Natu
ro A
id P
harm
aceu
�cal
Inc.
Map
le R
idge
, B.C
., V2
X 8G
1, C
anad
a
ww
w.vi
taai
d.co
m
28 servings
without FOS | sans FOS
Vegan Fo
rmula
s
Form
ules
Vegan
Ultra
PB100+ DFUltra-PB100+ DFPowdered, high-dose probiotic formula for easy dose adjustment. Also suitable when higher dose is desired, as in inflammatory bowel diseases (IBD).
Key Features:• Dairy-Free
• Multi-Strains (10-13)
• Bile and acid resistance test (no enteric coating required)
• Human-gut anchoring ability test
• Antibiotic resistance panel to ensure safety
• 24-month Stability Test
Dairy Free / Sans produits laitiers
Helps to manage acute infectious diarrhoea, reduce
the risk of antibiotic-associated diarrhoea, and
support gastrointestinal health.
Contrôle de la diarrhée infectieuse aiguë; réduction
du risque de diarrhée associée aux antibiotiques;
and contribue à soutenir la santé gastrointestinale.
Ingr
edie
nts/
Ingr
édie
nts (
per/
par
caps
ule)
:
Lact
obac
illus
acid
ophi
lus (
LA-1
4)...
......
......
......
......
.6 b
illio
n/m
illia
rds c
fu
Lact
obac
illus
rham
nosu
s (LR
-32)
......
......
......
......
.....2
bill
ion/
mill
iard
s cfu
Lact
obac
illus
case
i (LC
-11)
......
......
......
......
......
......
..5 b
illio
n/m
illia
rds c
fu
Lact
obac
illus
saliv
ariu
s (LS
-33)
......
......
......
......
......
..1 b
illio
n/m
illia
rds c
fu
Bifid
obac
teriu
m b
ifidu
m (B
B-06
).....
......
......
......
......
1 bi
llion
/mill
iard
s cfu
Bifid
obac
teriu
m la
ctis (
BL-0
4)...
......
......
......
......
......
5 bi
llion
/mill
iard
s cfu
Stre
ptoc
occu
s the
rmop
hilu
s (ST
-21)
......
......
......
......
2 bi
llion
/mill
iard
s cfu
Bifid
obac
teriu
m b
reve
(BB-
03)..
......
......
......
......
....1
.5 b
illio
n/m
illia
rds c
fu
Lact
obac
illus
pla
ntar
um (L
P-11
5)...
......
......
......
....1
.5 b
illio
n/m
illia
rds c
fu
Lact
obac
illus
rham
nosu
s (HN
001)
......
......
......
......
...2
billi
on/m
illia
rds c
fu
Lact
obac
illus
rham
nosu
s (GG
).....
......
......
......
......
...3
bill
ion/
mill
iard
s cfu
*May
con
tain
up
to 5
5 bi
llion
via
ble
cells
per
cap
sule
at
the
�me
of
man
ufac
ture
./ Pe
ut co
nten
ir ju
squ’
à 55
mill
iard
s de
cellu
les v
iabl
es p
ar
caps
ule
au m
omen
t de
la fa
brica
�on.
Non-
med
icina
l Ing
redi
ents
/ Ing
rédi
ents
Non
-méd
icina
ux: L
-leuc
ine,
mal
tode
xtrin
/ mal
tode
xtrin
e, p
ullu
lan/
hyp
rom
ello
se (c
apsu
le)
Sugg
este
d Us
e/ U
�lisa
�on
Sugg
érée
:
For G
ener
al U
se: T
ake
1 ca
psul
e 1
- 3 �
mes
per
day
, or a
s dire
cted
by
a
heal
th ca
re p
rac�
�one
r. Fo
r Acu
te In
fec�
ous D
iarr
hea:
Tak
e 1
caps
ule,
3 �m
es a
day
. For
Red
ucin
g th
e Ri
sk o
f An�
bio�
c-As
socia
ted
Diar
rhea
:
Take
2 ca
psul
es, 2
-3 �
mes
a d
ay./
À us
age
géné
ral:
Pren
dre
1 ca
psul
e 1
à 3
fois
par
jour
, ou
suivr
e le
s
cons
eils
d’u�
lisa�
on d
e vo
tre p
ra�c
ien
de s
anté
. Po
ur l
a di
arrh
ée
infe
c�eu
se a
iguë
: Pr
endr
e 1
caps
ules
, 3 f
ois
par
jour
. Réd
uc�o
n du
risqu
e de
dia
rrhé
e as
socié
e au
x an�
bio�
ques
: Pre
ndre
2 ca
psul
es, 2
à 3
fois
par j
our.
Cau�
on/ M
ise e
n Ga
rde:
If yo
u ha
ve fe
ver,
vom
i�ng
, blo
ody
diar
rhoe
a or
seve
re a
bdom
inal
pai
n,
cons
ult a
hea
lth c
are
prac
��on
er p
rior t
o us
e. If
sym
ptom
s of d
iges
�ve
upse
t (e.
g. d
iarr
hea)
occ
ur, w
orse
n, o
r per
sist b
eyon
d 3
days
, disc
on�n
ue
use
and
cons
ult a
hea
lth ca
re p
rac�
�one
r. Do
not
use
this
prod
uct i
f you
have
an im
mun
e-co
mpr
omise
d co
ndi�
on (e
.g. A
IDS,
lym
phom
a, p
a�en
ts
unde
rgoi
ng lo
ng-te
rm co
r�co
ster
oid
treat
men
t)./
Si vo
us so
uffre
z de
fièvr
e, d
e vo
miss
emen
ts, d
e di
arrh
ée sa
ngla
nte
ou d
e
doul
eurs
abd
omin
ales
inte
nses
, con
sulte
r un
pra�
cien
de s
oins
de
sant
é
avan
t d'
en fa
ire l'
usag
e. S
i des
sym
ptôm
es d
e tro
uble
s di
ges�
fs (p
. ex.
diar
rhée
) se
man
ifest
ent,
s'agg
rave
nt e
t/ou
per
siste
nt a
u-de
là d
e 3
jour
s,
cess
er l'
u�lis
a�on
et
cons
ulte
r un
pra
�cie
n de
soi
ns d
e sa
nté.
Si v
ous
souff
rez d
'un
défic
it im
mun
itaire
(p. e
x. sid
a, ly
mph
ome,
pa�
ents
subi
ssan
t
un tr
aite
men
t pro
long
é au
x cor
�cos
téro
ïdes
), ne
pas
u�l
iser c
e pr
odui
t.
Stor
e un
der
refri
gera
�on
(bel
ow 8
˚C).
Plea
se fi
nish
con
sum
ing
the
prod
uct w
ithin
60
days
a�e
r ope
ning
. Do
not u
se if
cap
seal
is b
roke
n. /
Mai
nten
ir so
us ré
frigé
ra�o
n (a
u-de
ssou
s de
8˚C)
. S’il
vous
pla
ît te
rmin
er
le p
rodu
it es
t co
nsom
mé
dans
les
60 jo
urs
aprè
s ou
vert
ure.
Ne
pas
u�lis
er si
le sc
eau
du ca
puch
on e
st b
risé.
Man
ufac
ture
d by
/ Fab
riqué
par
: Nat
uro
Aid
Phar
mac
eu�c
al In
c.
Map
le R
idge
, B.C
., V2
X 8G
1, C
anad
a |
ww
w.vi
taai
d.co
m
56 Vegetarian Capsules
Supreme
PB30+ DF without FOS | sans FOS
Vegan Fo
rmula
s
Form
ules
Vegan
Dairy Free / Sans produits laitiers
Helps to manage acute infectious diarrhoea, reduce the risk of antibiotic-associated diarrhoea, and support gastrointestinal health.
Contrôle de la diarrhée infectieuse aiguë; réduction du risque de diarrhée associée aux antibiotiques; and contribue à soutenir la santé gastrointestinale.
Ingr
edie
nts/
Ingr
édie
nts (
per/
par
cap
sule
):La
ctob
acill
us a
cido
philu
s (LA
-14)
......
......
......
......
....6
bill
ion/
mill
iard
s cfu
Lact
obac
illus
rham
nosu
s (LR
-32)
......
......
......
......
.....2
bill
ion/
mill
iard
s cfu
Lact
obac
illus
cas
ei (L
C-11
).....
......
......
......
......
......
...5
bill
ion/
mill
iard
s cfu
Lact
obac
illus
saliv
ariu
s (LS
-33)
......
......
......
......
......
..1 b
illio
n/m
illia
rds c
fuBi
fidob
acte
rium
bifi
dum
(BB-
06)..
......
......
......
......
...1
billi
on/m
illia
rds c
fuBi
fidob
acte
rium
lacti
s (BL
-04)
......
......
......
......
......
...5
billi
on/m
illia
rds c
fuSt
rept
ococ
cus t
herm
ophi
lus (
ST-2
1)...
......
......
......
...2
billi
on/m
illia
rds c
fuBi
fidob
acte
rium
bre
ve (B
B-03
).....
......
......
......
......
.1.5
bill
ion/
mill
iard
s cfu
Lact
obac
illus
pla
ntar
um (L
P-11
5)...
......
......
......
....1
.5 b
illio
n/m
illia
rds c
fuLa
ctob
acill
us rh
amno
sus (
HN00
1)...
......
......
......
......
2 bi
llion
/mill
iard
s cfu
Lact
obac
illus
rham
nosu
s (GG
).....
......
......
......
......
...3
bill
ion/
mill
iard
s cfu
*May
con
tain
up
to 5
5 bi
llion
via
ble
cells
per
cap
sule
at
the
�me
of
man
ufac
ture
./ P
eut c
onte
nir j
usqu
’à 5
5 m
illia
rds d
e ce
llule
s via
bles
par
ca
psul
e au
mom
ent d
e la
fabr
ica�
on.
Non
-med
icin
al In
gred
ient
s/ In
gréd
ient
s Non
-méd
icin
aux:
L-le
ucin
e,
mal
tode
xtrin
/ mal
tode
xtrin
e, p
ullu
lan/
hyp
rom
ello
se (c
apsu
le)
Sugg
este
d U
se/
U�l
isa�
on S
uggé
rée:
Fo
r Gen
eral
Use
: Tak
e 1
caps
ule
1 - 3
�m
es p
er d
ay, o
r as d
irect
ed b
y a
heal
th c
are
prac
��on
er. F
or A
cute
Infe
c�ou
s Dia
rrhe
a: T
ake
1 ca
psul
e,
3 �m
es a
day
. For
Red
ucin
g th
e Ri
sk o
f An�
bio�
c-As
soci
ated
Dia
rrhe
a:
Take
2 c
apsu
les,
2-3
�m
es a
day
./
À us
age
géné
ral:
Pren
dre
1 ca
psul
e 1
à 3
fois
par
jour
, ou
suiv
re le
s co
nsei
ls d’
u�lis
a�on
de
votr
e pr
a�ci
en d
e sa
nté.
Pou
r la
dia
rrhé
e in
fec�
euse
aig
uë:
Pren
dre
1 ca
psul
es,
3 fo
is pa
r jo
ur.
Rédu
c�on
du
risqu
e de
dia
rrhé
e as
soci
ée a
ux a
n�bi
o�qu
es: P
rend
re 2
cap
sule
s, 2
à 3
fois
par j
our.
Cau�
on/
Mis
e en
Gar
de:
If yo
u ha
ve fe
ver,
vom
i�ng
, blo
ody
diar
rhoe
a or
sev
ere
abdo
min
al p
ain,
co
nsul
t a h
ealth
car
e pr
ac��
oner
prio
r to
use.
If s
ympt
oms
of d
iges
�ve
upse
t (e.
g. d
iarr
hea)
occ
ur, w
orse
n, o
r per
sist b
eyon
d 3
days
, disc
on�n
ue
use
and
cons
ult a
hea
lth c
are
prac
��on
er. D
o no
t use
this
prod
uct i
f you
ha
ve a
n im
mun
e-co
mpr
omise
d co
ndi�
on (e
.g. A
IDS,
lym
phom
a, p
a�en
ts
unde
rgoi
ng lo
ng-te
rm c
or�c
oste
roid
trea
tmen
t)./
Si v
ous
souff
rez
de fi
èvre
, de
vom
issem
ents
, de
diar
rhée
san
glan
te o
u de
do
uleu
rs a
bdom
inal
es in
tens
es, c
onsu
lter
un p
ra�c
ien
de s
oins
de
sant
é av
ant
d'en
fai
re l'
usag
e. S
i des
sym
ptôm
es d
e tr
oubl
es d
iges
�fs
(p. e
x.
diar
rhée
) se
man
ifest
ent,
s'agg
rave
nt e
t/ou
per
siste
nt a
u-de
là d
e 3
jour
s, ce
sser
l'u�
lisa�
on e
t co
nsul
ter
un p
ra�c
ien
de s
oins
de
sant
é. S
i vou
s so
uffre
z d'u
n dé
ficit
imm
unita
ire (p
. ex.
sida
, lym
phom
e, p
a�en
ts su
biss
ant
un tr
aite
men
t pro
long
é au
x cor
�cos
téro
ïdes
), ne
pas
u�l
iser c
e pr
odui
t.
Stor
e un
der
refr
iger
a�on
(be
low
8˚C
). Pl
ease
fini
sh c
onsu
min
g th
e pr
oduc
t with
in 6
0 da
ys a
�er o
peni
ng. D
o no
t use
if c
ap se
al is
bro
ken.
/
Mai
nten
ir so
us ré
frig
éra�
on (a
u-de
ssou
s de
8˚C)
. S’il
vou
s pla
ît te
rmin
er
le p
rodu
it es
t co
nsom
mé
dans
les
60 jo
urs
aprè
s ou
vert
ure.
Ne
pas
u�lis
er si
le sc
eau
du c
apuc
hon
est b
risé.
Man
ufac
ture
d by
/ Fab
riqué
par
: Nat
uro
Aid
Phar
mac
eu�c
al In
c.M
aple
Rid
ge, B
.C.,
V2X
8G1,
Can
ada
| w
ww
.vita
aid.
com
56 Vegetarian Capsules
Supreme
PB30+ DF without FOS | sans FOS
Vegan
Form
ulas
Formul
es V
egan
• ATCC®-Registered - strain identity, safety, and quality monitored
• Contain up to 200% viable cells when manufactured
• Suitable for all age groups and tailored to meet specific needs
• Comes with or without Fructooligosaccharides (FOS) prebiotic (except for Baby & Mom-PB15+)
Clinical Evidence of Featured StrainsBifidobacterium bifidum Bb-06 [1]
B. bifidum is proved to help reduce risk of cold & flu as well as increase recovery time.
A study with 581 academically stressed undergraduate students receive 3 billion cfu/day of probiotic L. helveticus, B. infantis, B. bifidum or placebo for 6 weeks. The results showed B. bifidum supplementation resulted in a greater proportion of healthy days and a lower percentage of students reporting a day of cold/flu.
Bifidobacterium lactis BL-04 [2]
B. lactis Bl-04 is effective in supporting the immune system and reduce risk of repiratory infection in a clinical trial.
A total of 465 participants (241 males; 224 females) were randomly divided into 3 groups. One group had 2 billion cfu of B. lactis BL-04 only; the second group had 5 billion cfu of L. acidophilus NCFM + B. lactis BI-07, and both groups were compared to placebo. A 5-month intervention showed that only the B. lactis BL-04 group had significantly lower risk of URTI by 27% (risk ratio of 0.73; p=0.02) compared to placebo. BL-04 also delayed the first onset of URTI by ~0.8 month.
Lactobacillus rhamnosus (Lr-32, HN001, GG)L. rhamnosus is part of normal human gut flora. Among many other benefits, L. rhamnosus is known to balance the immune system, as clinical trials have shown efficacy on prevention/recovery of infectious disease, allergies, and atopic dermatitis.
Lactobacillus rhamnosus HN001L. rhamnosus HN001 has been clinically shown to reduce risk of allergies (skin and respiratory systems) in children, as well as gestational diabetes in pregancy.
Eczema and Allergic sensitization: A 6-year RCT [3]
A double-blind, randomized, placebo-controlled trial of 316 mothers and their infants (placebo, n=159; supplement, n=157). Pregnant mothers were supplemented daily from 5 weeks pre-term to 6 months post-term if breastfeeding. Infants were supplemented daily from birth until 2 years old.
At 2 years of age, the prevalence of eczema decreased by 49% (p=0.01) with supplementation. This effect persisted until 6 years of age with 44% lower prevalence (p=0.01).
In addition, L. rhamnosus HN001 showed a 31% decreased the prevalence of positive skin-prick tests (p=0.04), and 62 % less relative risk of rhinoconjunctivits (rhinitis and red eyes).
Gestational diabetes mellitus (GDM) risk reduction [4]
In a RCT, pregnant women were randomized at 14-16 weeks of gestation to receive 6 billion of L. rhamnosus HN001 (n=212) or placebo (n=211) daily. At 24-30 weeks, GDM prevalence was significantly lower in the HN001 group, 2.1 % (CI=0.6-5.2), vs. 6.5 % (CI=3.5-10.9) in the placebo group (P=0.03). Significant association of lower GDM was reported in women aged ≥35 years (RR=0.31; CI=0.12-0.81, P=0.009) and those with a history of GDM (RR=0.00; CI=0.00-0.66, P=0.004).
Lactobacillus rhamnosus GGL. rhamnosus GG is by far the most studied probiotic strain. Studies have shown its effectiveness from general to serious GI/ repiratory/ dental infections, as well as reduce allergy and IBS in infants and children.
Gastrointestinal Health [5], [6], [7]
L. rhamnosus GG is known to be the most effective probiotic in reducing both severity and duration of acute onset infectious diarrhea (overall reduction 1.05 days). Several systemic review and meta-analysis studies also suggest a protective effect of L. rhamnosus GG against antibiotic associated diarrhea, preterm neonatal Candida, Clostridium difficile induced colitis, vancomycin-resistant enterococci, and improves abdominal pain in children with IBS (NNT=4).
Respiratory and Atopic Diseases PreventionIn additional to GI conditions, L. rhamnosus GG was effective in reducing the risk of respiratory tract infection in preterm infants and hospitalized children, as well as in protecting hospitalized patients and patients with cystic fibrosis against Pseudomonas aeruginosa pneumonia.Another area for L. rhamnosus GG application is in the pre- & post-natal period. Prenatal supplementation of L. rhamnosus GG was shown to promote a beneficial profile dominated by bifidobacteria in neonates. A RCT involving 105 infants fed standard infant formula supplemented with L. rhamnosus GG developed better.[8] Two meta-analyses provided best evidence for L. rhamnosus GG supplementation in mothers and infants in long-term prevention of atopic dermatitis.[9]
Oral HealthLast but not least, milk containing L. rhamnosus GG has been demonstrated to reduce dental caries and lower streptococcus mutans levels from dental plaque and saliva. [10]
Lactobacillus reuteri 1E1L. reuteri is helpful in reducing the time of crying in infantile colic and promote recovery in acute infectious diarrhea.
One meta-analysis of 3 RCTs on infantile colic (n=209) showed
Antibiotic Resistance Test & Genome Database
Bacteria including probiotics are capable of sharing their genetic materials (eg. plasmids) with each other; such nature could be problematic as the antibiotic resistant genes from probiotics can potentially be passed onto the pathogenic bacteria. Antibiotic resistance test ensures that the probiotic strains are sensitive to at least 3 commonly used antibiotics, especially the last-resort ones such as Vancomycin, and Carbapenems. To take the safety issue further, all probiotics should have their genomes assayed and registered with well-known genome databases so that their safety and efficacy can continue to be monitored.
“Human Strains” v.s. “Human Gut Anchoring Strains”
Humans are born sterile before they encounter a variety of bacteria from the surrounding environment. Therefore, even though “human strain” is one of the highly marketed features in probiotic formulas, there is no strain from human origin. Any strains of bacteria succeeded in colonizing in their host human become the “human strains”. Probiotics’ human-gut anchoring ability can actually be tested via their adhesion to human intestinal cell lines – HT-29 and Caco-2.
L. reuteri supplementation reduced risk of infant crying time at 14 and 21 days (NNT = 2). [11]
The other meta-analysis of 8 RCTs involving 1,229 children found that L. reuteri supplementation reduced the duration (25 hours) of acute infectious diarrhea and increased the cure rate on days 1 and 2. [12]
Bifidobacterium infantis Bi-26B. infantis is passed from mother to baby during vaginal birth and is considered a superior colonizer of infant gut due to its unique ability to digest oligosaccharides in the human milk.[13]
Naturally, B. infantis helps with proper metabolic and immune development of the infants. However, with the growing practice of C-section, avoidance of breastfeeding, and exposure to antibiotics in mother’s life, colonization of B. infantis has been largely eliminated in babies born today, which leads to dysbiosis and detrimental consequences in the baby’s life.
Preclinical data has shown that B. infantis has anti-inflammatory activity, and could decreases intestinal permeability in premature intestinal cells. In premature infants, B. infantis was found to decreases Enterobacteriaceae (e.g. Salmonella, E. coli, Klebsiella, and Shigella) and reduce the risk of necrotizing enterocolitis. Colonization with B. infantis is also associated with better weight gain, increased thymic index, and better response to vaccines.
In a phase I clinical trial, B. infantis supplement was safe and well-tolerated, and showed fewer and better formed stool in healthy term breastfed infants, compared to “frequent, watery” stool in the control group. [14]
Multiple clinical trials and a meta-analysis found B. infantis supplementation significantly relives many IBS symptoms (abdominal pain, gas/bloating, bowel dysfunction, etc), as well as normalization of inflammation marker. The effect on bloating/distension was more prominent with B. infantis in composite formula.[15,16, 17,18]
Saccharomyces boulardiiS. boulardii is the most studied yeast probiotic. Research has documented efficacy of S. boulardii for the treatment of acute gastroenteritis, especially in children, and for the prevention of antibiotic-associated diarrhea, both in adults and children. There is also evidence supporting the use of S. boulardii to increase the eradication rate of Helicobacter pylori and decrease antibiotic side effects. [19]
Other clinical utility for S. boulardii include improved weight gain and feeding tolerance in preterm infants [20], reduced bacterial translocation and inflammatory marker in HIV patients [21], as well as lowered coronary artery disease biomarker in patients with hypercholesterolemia. [22]
Yeast Probiotic vs. Yeast InfectionSome may have concern that taking yeast probiotic such as
S. boulardii might lead to Candida infection in otherwise healthy individuals has not been substantiated by clinical evidence. In fact, preclinical data showed inhibitory effect of S. boulardii on the ability to form filaments and biofilms of C. albicans [25]; S. boulardii could also reduce pro-inflammatory cytokine IL-8 expressed by C. albicans-infected intestinal cells.[26]
In a clinical study of preterm infants with low birth weight, prophylactic S. boulardii is as effective as nystatin for the prevention of fungal colonization and invasive infection. Moreover, S. boulardii reduce incidence and number of sepsis attacks significantly more than nystatin and showed better feeding intolerance.[27]
Why Single Strain S. boulardii?Although combination probiotics with S. boulardii are available on the market, existing clinical trials have been
utilizing single-strain preparation. Possible antagonism may exist between “the yeast & bacteria” and decrease therapeutic efficacy.[23] In a RCT on children with acute rotavirus diarrhea, significantly shortened duration of fever & diarrhea was seen with single-strain S. boulardii, but not with combination of S. boulardii + other probiotics. [24]
Dairy Free ProbioticSize
Supreme-PB30+56 veg caps*
**Ultra-PB100+28 servings (1 tsp)*
Optimum-PB10+56 veg caps*
**Baby & Mom-PB15+56 servings (1/2 tsp)
S. boulardii84 veg caps
Viable cells at time of manufacture (CFU) Up to 55 billion Up to 200 billion Up to 18 billion Up to 25 billion
Lactobacillus acidophilus La-14 6 billion 15 billion 2.1 billion 1.5 billion
Lactobacillus rhamnosus Lr-32 2 billion 15 billion 1 billion 1.5 billion
Lactobacillus casei Lc-11 5 billion 10 billion 0.6 billion 1 billion
Lactobacillus salivarius Ls-33 1 billion 8 billion 0.6 billion 1 billion
Bifidobacterium bifidum Bb-06 1 billion 2 billion 0.4 billion 0.5 billion
Bifidobacterium lactis Bl-04 5 billion 12 billion 1.6 billion 1.5 billion
Streptococcus thermophilus St-21 2 billion 8 billion 0.5 billion 1 billion
Bifidobacterium breve Bb-03 1.5 billion 5 billion 0.6 billion 1 billion
Lactobacillus plantarum Lp-115 1.5 billion 15 billion 1.5 billion 1.5 billion
Lactobacillus rhamnosus GG 3 billion 6 billion 1.2 billion 2 billion
Lactobacillus rhamnosus HN001 2 billion 3 billion 2 billion
Bifidobacterium infantis Bi-26 1 billion 1 billion
Lactobacillus reuteri 1E1 1 billion 0.5 billion
Saccharomyces boulardii 5 billion
*FOS and FOS-free formula available. **Powder form. Unit: CFU = colony-forming unit.
Manufactured by Naturo Aid Pharmaceutical Inc. in accordance with Good Manufacturing Practices | NHPD-GMP site license #300391#302-20285 Stewart Crescent, Maple Ridge, BC, V2X 8G1, Canada
Canada & US: 1-800-490-1738 | Other: 1-604-465-1688 | Fax: 1-604-465-1299Email: [email protected] | Fore more information, please visit our website: www.vitaaid.com
For Education Purpose Only: The entire contents are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this presentation. All statements in this article have not been evaluated by the Food and Drug Administration and are not intended to be used to diagnose, treat, or prevent any diseases.
Reference:1. Langkamp-Henken, B., Rowe, C. C., Ford, A. L., Christman, M. C., Nieves,
C., Khouri, L., ... & Dahl, W. J. (2015). Bifidobacterium bifidum R0071 results in a greater proportion of healthy days and a lower percentage of academically stressed students reporting a day of cold/flu: a randomised, double-blind, placebo-controlled study. British Journal of Nutrition, 113(3), 426-434.
2. West, N. P., Horn, P. L., Pyne, D. B., Gebski, V. J., Lahtinen, S. J., Fricker, P. A., & Cripps, A. W. (2014). Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals. Clinical Nutrition, 33(4), 581-587.
3. Wickens, K., Stanley, T. V., Mitchell, E. A., Barthow, C., Fitzharris, P., Purdie, G., ... & Crane, J. (2013). Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization?. Clinical & Experimental Allergy, 43(9), 1048-1057.
4. Wickens, K. L., Barthow, C. A., Murphy, R., Abels, P. R., Maude, R. M., Stone, P. R., … Crane, J. (2017). Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial. The British Journal of Nutrition, 117(6), 804–813.
5. Goldenberg, J. Z., Lytvyn, L., Steurich, J., Parkin, P., Mahant, S., & Johnston, B. C. (2015). Probiotics for the prevention of pediatric antibiotic-associated diarrhea. The Cochrane Library.
6. Yan, F., & Polk, D. B. (2012). Lactobacillus rhamnosus GG: an updated strategy to use microbial products to promote health. Functional food reviews (Print), 4(2), 77.
7. Segers, M. E., & Lebeer, S. (2014). Towards a better understanding of Lactobacillus rhamnosus GG - host interactions. Microbial Cell Factories, 13(Suppl 1), S7.
8. Szajewska, H., & Chmielewska, A. (2013). Growth of infants fed formula supplemented with Bifidobacterium lactis Bb12 or Lactobacillus GG: a systematic review of randomized controlled trials. BMC Pediatrics, 13, 185.
9. Wollina, U. (2017). Microbiome in atopic dermatitis. Clinical, Cosmetic and Investigational Dermatology, 10, 51–56.
10. Näse, L., Hatakka, K., Savilahti, E., Saxelin, M., Pönkä, A., Poussa, T., ... & Meurman, J. H. (2001). Effect of long–term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries research, 35(6), 412-420.
11. Anabrees, J., Indrio, F., Paes, B., & AlFaleh, K. (2013). Probiotics for infantile colic: a systematic review. BMC pediatrics, 13(1), 186.
12. Urbańska, M., Gieruszczak-Białek, D., & Szajewska, H. (2016). Systematic review with meta-analysis: Lactobacillus reuteri DSM 17938 for diarrhoeal diseases in children. Alimentary pharmacology & therapeutics, 43(10), 1025-1034.
13. Underwood, M. A., German, J. B., Lebrilla, C. B., & Mills, D. A. (2015). Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut. Pediatric research, 77, 229.
14. Smilowitz, J. T., Moya, J., Breck, M. A., Cook, C., Fineberg, A., Angkustsiri, K., & Underwood, M. A. (2017). Safety and tolerability of Bifidobacterium longum subspecies infantis EVC001 supplementation in healthy term breastfed infants: a phase I clinical trial. BMC pediatrics, 17(1), 133.
15. O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., ... & Quigley, E. M. (2005). Lactobacillus and bifidobacterium in irritable bowel
syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology, 128(3), 541-551.
16. Whorwell, P. J., Altringer, L., Morel, J., Bond, Y., Charbonneau, D., O’mahony, L., ... & Quigley, E. M. (2006). Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. The American journal of gastroenterology, 101(7), 1581.
17. Ringel-Kulka, T., McRorie, J., & Ringel, Y. (2016). Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the benefit of the probiotic Bifidobacterium infantis 35624 in non-patients with symptoms of abdominal discomfort and bloating. The American journal of gastroenterology.
18. Yuan, F., Ni, H., Asche, C. V., Kim, M., Walayat, S., & Ren, J. (2017). Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Current Medical Research and Opinion, 1-7.
19. Szajewska, H., Konarska, Z., & Kołodziej, M. (2016). Probiotic bacterial and fungal strains: claims with evidence. Digestive Diseases, 34(3), 251-259.
20. Xu, L., Wang, Y., Wang, Y., Fu, J., Sun, M., Mao, Z., & Vandenplas, Y. (2016). A double-blinded randomized trial on growth and feeding tolerance with Saccharomyces boulardii CNCM I-745 in formula-fed preterm infants. Jornal de Pediatria (Versão em Português), 92(3), 296-301.
21. Villar-García, J., Güerri-Fernández, R., Moya, A., González, A., Hernández, J. J., Lerma, E., … Knobel, H. (2017). Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial. PLoS ONE, 12(4), e0173802.
22. Ryan, J. J., Hanes, D. A., Schafer, M. B., Mikolai, J., & Zwickey, H. (2015). Effect of the Probiotic Saccharomyces boulardii on Cholesterol and Lipoprotein Particles in Hypercholesterolemic Adults: A Single-Arm, Open-Label Pilot Study. Journal of Alternative and Complementary Medicine, 21(5), 288–293.
23. Kelesidis, T., & Pothoulakis, C. (2012). Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therapeutic Advances in Gastroenterology, 5(2), 111–125.
24. Grandy, G., Medina, M., Soria, R., Terán, C. G., & Araya, M. (2010). Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children. BMC Infectious Diseases, 10, 253.
25. Krasowska, A., Murzyn, A., Dyjankiewicz, A., Łukaszewicz, M., & Dziadkowiec, D. (2009). The antagonistic effect of Saccharomyces boulardii on Candida albicans filamentation, adhesion and biofilm formation. FEMS yeast research, 9(8), 1312-1321
26. Murzyn, A., Krasowska, A., Augustyniak, D., Majkowska-Skrobek, G., Łukaszewicz, M., & Dziadkowiec, D. (2010). The effect of Saccharomyces boulardii on Candida albicans-infected human intestinal cell lines Caco-2 and Intestin 407. FEMS microbiology letters, 310(1), 17-23.
27. Demirel, G., Celik, I. H., Erdeve, O., Saygan, S., Dilmen, U., & Canpolat, F. E. (2013). Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants. European journal of pediatrics, 172(10), 1321-1326.